Contrasting Neos Therapeutics (NEOS) and Innocoll (INNL)

Neos Therapeutics (NASDAQ: NEOS) and Innocoll (NASDAQ:INNL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Neos Therapeutics and Innocoll’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neos Therapeutics -339.52% -551.26% -68.57%
Innocoll -1,051.20% N/A -138.53%

Institutional & Insider Ownership

46.0% of Neos Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Innocoll shares are held by institutional investors. 5.2% of Neos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Neos Therapeutics and Innocoll’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neos Therapeutics $9.15 million 30.11 -$83.33 million ($3.42) -2.78
Innocoll N/A N/A N/A ($1.66) -1.42

Innocoll has lower revenue, but higher earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than Innocoll, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Neos Therapeutics and Innocoll, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neos Therapeutics 0 1 4 0 2.80
Innocoll 0 2 1 0 2.33

Neos Therapeutics currently has a consensus price target of $16.20, suggesting a potential upside of 70.53%. Innocoll has a consensus price target of $3.00, suggesting a potential upside of 27.66%. Given Neos Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Neos Therapeutics is more favorable than Innocoll.

Summary

Neos Therapeutics beats Innocoll on 8 of the 11 factors compared between the two stocks.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Innocoll Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply